Enhanced platelet release of superoxide anion in systemic hypertension: Role of AT1 receptors

Journal of Hypertension

Volumn 22, Issue 6, 2004, Pages 1151-1156

  Germanò, Giuseppe ^a   Sanguigni, Valerio ^b   Pignatelli, Pasquale ^a   Caccese, Daniela ^b   Lenti, Luisa ^a   Ragazzo, Maddalena ^a   Lauro, Renato ^b   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

AT1 receptor; Hypertension; Oxidative stress; Platelets; Superoxide anion

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COLLAGEN; DIPHENYLIODONIUM SALT; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; OXIDOREDUCTASE INHIBITOR; OXYGEN RADICAL; SUPEROXIDE;

ADULT; ARTICLE; BLOOD PRESSURE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOFLUOROMETRY; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE RELEASE REACTION;

EID: 2642521178     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200406000-00016     Document Type: Article

References (29)

1. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular disease. The role of oxidant stress. Circ Res 2000; 87:840-844.
2. Zalba G, Beaumont J, San Josè G, Fortuno MA, Diez J. Vascular oxidant stress: molecular mechanism and pathophysiological implications. J Physiol Biochem 2000; 56:57-64.
3. Beckman JS, Beckman TW, Chen J,Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87:1620-1624.
4. Zalba G, Beaumont J, San Josė G, Fortuno MA, Diez J. Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction? Nephrol Dial Transplant 2001; 16 (Suppl):2-5.
5. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
6. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000; 101:1722-1728.
7. Freedman JE, Keaney JF. Nitric oxide and superoxide detection in human platelets. Meth Enzymol 1999; 301:61-70.
8. Liochev SI, Fridovich I. Lucigenin (bis-N-methylacridinium) as a mediator of superoxide anion production. Arch Biochem Biophys 1997; 337:115-120.
9. Afanas'ev IB, Ostrachovitch EA, Korkina LG. Lucigenin is a mediator of cytochrome C reduction but not of superoxide production. Arch Biochem Biophys 1999; 366:267-274.
10. Vasquez-Vivar J, Hogg N, Pritchard A Jr, Martasek P, Kalyanaraman B. Superoxide anion formation from lucigenin: an electron spin resonance spin-trapping study. FEBS Lett 1997; 403:127-130.
11. Leo R, Praticò D, Luliano L, Pulcinelli FM, Ghiselli A, Pignatelli P, et al. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation 1997; 95:885-891.
12. Tarpey M, Fridovich L. Methods of detection of vascular reactive species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ Res 2001; 89:224-236.
13. Benov L, Sztejnberg L, Fridovich L. Critical evaluation of the use of hydroethidine as a measure of superoxide anion radical. Free Radic Biol Med 1998; 25:826-831.
14. Rothe G, Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2,7-dichlorofluorescin. J Leukoc Biol 1990; 47:440-448.
15. Lacy F, O'Connor DT, Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 1998; 16:291-303.
16. Mehta JL, Lopez LM, Chen L, Cox OE. Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol 1994; 74:901-905.
17. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998; 91:484-490.
18. Marcus AJ, Silk ST, Safier B, Ullman HL. Superoxide production and reducing activity in human platelets. J Clin Invest 1977; 59:149-158.
19. Berry C, Hamilton CA, Brosnan J, Magill FG, Berg GA, McMurray JJ, Dominiczak AF. Investigation into the sources of superoxide in human blood vessels. Angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 101:2206-2212.
20. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension. The role of superoxide anion. Hypertension 1999; 34:539-545.
21. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
22. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346:1954-1962.
23. Liu EC, Hedberg A, Goldenberg HJ, Harris DN, Webb ML. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 1992; 44:89-99.
24. Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, Jimenez AM, Gonzalez-Fernandez F, Rico LA, et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17:447-452.
25. Monton M, Jimenez A, Nunez A, Lopez-Blaya A, Farre J, Gomez J, et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000; 35:906-913.
26. Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II AT receptor antagonist irbesartan prevents thromboxane A-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000; 292:238-246.
27. Buczko W, Matys T, Pawlak R, Kucharewicz I, Chabielska E. Studies on the antithrombotic action of AT1 receptor antagonists. Med Sci Monit 2001; 7:600-605.
28. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40:521-527.
29. Hayek T, Pavlotzky E, Hamoud S, Coleman R, Keidar S, Aviram M, Kaplan M. Tissue angiotensin-converting-enzime (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis. Studies in ACE-knockout mice type 2. Arterioscler Thromb Vasc Biol 2003; 23:2090-2096.